Mia's Feed
Medical News & Research

Gut Microbiome in Extremely Low-Birth-Weight Infants Influences Lung Damage Development

Gut Microbiome in Extremely Low-Birth-Weight Infants Influences Lung Damage Development

Share this article

New research links gut fungi in very-low-birth-weight infants to the development of lung damage, suggesting potential for innovative therapies targeting the microbiome.

2 min read

Recent research published in the journal Microbiome reveals a significant link between the gut fungi microbiome, known as the mycobiome, in very-low-birth-weight (VLBW) preterm infants and the development of oxygen-induced lung injury, particularly bronchopulmonary dysplasia (BPD). Extremely preterm infants, especially those weighing less than 3.3 pounds, often require high oxygen levels and mechanical ventilation, which can damage immature lungs and lead to BPD, a leading cause of mortality among these vulnerable infants.

In a comprehensive study conducted by researchers from the University of Alabama at Birmingham and the University of Tennessee Health Science Center, the gut fungi present in the second week of life, before clinical symptoms of BPD appear, were analyzed. The study examined stool samples collected from infants within the first two weeks after birth. Findings indicated that the diversity and composition of the infants' gut mycobiome differed markedly between those who later developed BPD and those who did not. Notably, bacterial differences were not significant in early stool samples.

To explore causality, researchers transferred stool samples—either associated with BPD prediction or not—into female mice to observe the effects. Mice receiving stool associated with BPD exhibited more severe lung injury, echoing the human condition. Furthermore, when antifungal treatments were administered to the dams of these pups, the severity of lung damage was reduced, suggesting that fungi play a causal role in lung injury. Conversely, increasing fungal colonization with a Candida species intensified lung injury in the mouse model.

Dr. Kent Willis, one of the lead researchers, commented that initial fungal colonization patterns in the gut might influence the development of BPD in preterm infants. The research highlights the potential for targeting the gut mycobiome as a therapeutic strategy to prevent or mitigate lung damage in these infants. The study underscores that a balanced and uniform fungal community may confer resistance to BPD, while discordant mycobiomes could predispose infants to disease.

This investigation adds a new dimension to understanding neonatal lung disease, emphasizing the importance of the gut microbiota, particularly fungi, in early development and long-term health outcomes in preterm infants.

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

Brain Insulin Resistance as a Possible Link Between Alzheimer's Disease and Epilepsy

Emerging research reveals that insulin resistance in the brain may be a critical factor connecting Alzheimer's disease and epilepsy, opening new avenues for treatment approaches targeting metabolic pathways.

Urgent Need to Strengthen Canada's Oncology Workforce Amid Advanced Cancer Treatments

Canada faces the urgent need to expand and adapt its oncology workforce to meet the rising demands of advanced cancer treatments and improved survival rates. Experts highlight strategies for sustainable, high-quality cancer care amid ongoing advances.

New Insights into the Origins of Treatment-Resistant Childhood Leukemia

New research uncovers the role of stem cell-like cells in treatment resistance and relapse of pediatric leukemia, paving the way for targeted therapies to improve outcomes.

Early Detection of Brain Changes in Down Syndrome Linked to Alzheimer's Disease

A recent study reveals that structural brain changes in the medial temporal lobe of individuals with Down syndrome can begin up to 15 years before Alzheimer's symptoms appear, opening new avenues for early diagnosis and intervention.